Products

OphtAI
OphtAI
Clinical Decision Support & Reference
OphtAI is an AI platform that analyzes retinal photos to detect the main pathological risks to the retina, including Diabetic Retinopathy, Glaucoma, and AMD, providing real-time analysis and detailed PDF reports.

See all 1 product →

About OphtAI

OphtAI is a French healthcare AI company specializing in artificial intelligence for ophthalmology. It was formed as a joint venture between Evolucare, a key player in hospital IT systems, and ADCIS, an expert in image analysis. The company’s solutions are designed to assist ophthalmology professionals in addressing the increasing demands of patient care, including a wider range of activities and diseases, and a growing number of patients requiring follow-up, care, or screening. OphtAI’s technology aims to optimize organizational workflows and enhance diagnostic performance, allowing specialists to focus on complex cases and high-value activities while ensuring widespread and safe screening.

For physicians, OphtAI offers a CE-marked medical device that provides semi-automated screening and grading of various retinal pathologies. The AI analyzes retinal images to detect conditions such as diabetic retinopathy (DR), diabetic macular edema, glaucoma, and age-related macular degeneration (AMD). The system provides rapid, computer-aided diagnoses with explicable results through lesion mapping and confidence indexes. It also includes features like real-time image quality checks to avoid re-examinations, automated preliminary patient sorting based on criticality, and automated patient record filling. OphtAI’s solutions are compatible with standard field color retinographs and can be integrated into existing IT tools and teleophthalmology platforms, facilitating collaboration among healthcare professionals and streamlining workflows. The company emphasizes that its AI does not replace clinicians but enhances their capabilities, reducing the risk of error, identifying early warning signs, and improving clinical decision-making.

Focus Areas

Artificial Intelligence Ophthalmology Diabetic Retinopathy Glaucoma Age-related Macular Degeneration Retinal Image Analysis Medical Device Tele-ophthalmology Screening Diagnosis

Business Intelligence

TechnologyCloud-native (Microsoft Azure), Deep Learning, AI operating system (integrated with various fundus cameras and ophthalmology software)

What Physicians Need to Know

Specialization in Retinal Pathologies
OphtAI specializes in the detection of major retinal pathologies, including Diabetic Retinopathy (DR), Glaucoma, and Age-related Macular Degeneration (AMD). They aim to expand this to around 40 pathologies and additional pathological signs.
AI-Powered Image Analysis
Their core offering is an AI solution that analyzes retinal photos captured with standard color retinographs to detect pathological risks in real-time.
High Diagnostic Performance
OphtAI boasts high sensitivity (up to 99%) and specificity (87%) in detecting retinal conditions, with performance comparable to human experts.
Rapid Screening and Diagnosis
The system provides results in seconds, significantly faster than traditional methods, and generates detailed PDF reports.
Medical Device Certification
OphtAI is a CE-marked medical device (Class IIa) and is working towards FDA certification, ensuring regulatory compliance and reliability.
Tele-ophthalmology and Remote Screening
The solution supports tele-ophthalmology, enabling large-scale automated screening and making eye care more accessible, especially in resource-limited settings.
Automated Workflow Integration
OphtAI can be accessed via a web browser, a desktop application, or through an API for integration into existing healthcare software, streamlining workflows and reducing repetitive tasks.
Focus on Diabetic Retinopathy
OphtAI has demonstrated superior sensitivity in detecting Diabetic Retinopathy, even outperforming human screeners in some studies, and can assess diabetic macular edema.
Glaucoma and AMD Detection
The platform also effectively screens for Glaucoma and Age-related Macular Degeneration (AMD), including early forms like Age-related Maculopathy.
Physician Tip

OphtAI's AI-powered retinal image analysis offers ophthalmologists and other eye care professionals a powerful tool to enhance diagnostic accuracy, improve screening efficiency, and optimize patient management. The system's high sensitivity and rapid analysis can aid in early detection of critical pathologies like Diabetic Retinopathy, Glaucoma, and AMD, allowing for timely intervention and potentially preventing vision loss. Its ability to provide detailed reports with lesion localization and confidence scores can support clinical decision-making. Furthermore, the tele-ophthalmology capabilities and integration options can help extend screening reach, particularly in underserved areas, and streamline workflows by automating initial image review and patient prioritization. This allows specialists to focus on complex cases and higher-value activities, ultimately improving the overall quality and accessibility of eye care. It's important to remember that AI is a tool to augment, not replace, clinical expertise.

OphtAI offers flexible integration options, including a web-based platform (OphtAI WEB), a desktop application (OphtAI APP), and an API for seamless integration into partners' software offerings. They are compatible with standard field color retinographs and have established partnerships for integration with various ophthalmology software and data management platforms like Topcon Harmony, Icare, CrystalVue, Area, Oplus, Optomed, Teo, and UmamiView. This allows for automated analysis of photos added to a PC directory and the automatic generation of PDF reports, directly within existing clinical workflows.

Products by OphtAI

1 product in the directory

OphtAI
OphtAI
Clinical Decision Support & Reference
OphtAI is an AI platform that analyzes retinal photos to detect the main pathological risks to the retina, including Diabetic Retinopathy, Glaucoma, and AMD, providing real-time analysis and detailed PDF reports.

What the Web Says

OphtAI is a company that develops AI-powered solutions for the early detection and screening of eye pathologies, such as Diabetic Retinopathy, glaucoma, and Age-related Macular Degeneration (AMD). Their technology aims to provide rapid and accurate analysis of retinal images, often outperforming human screeners in sensitivity. The company's solutions are available as a standalone web product or as an embedded solution in fundus cameras, and they are working towards FDA approval for their products in the US market.

Overall: Positive

Strengths

  • High sensitivity and specificity in detecting eye pathologies.
  • Faster image processing compared to other solutions.
  • Potential to reduce screening costs.
  • Backed by clinical specialists and scientific laboratories.
  • Aims to make AI accessible and easy to use in ophthalmological practice.
  • Capable of detecting multiple retinal pathologies.

Limitations

  • Limited public product reviews available on major platforms like G2, Glassdoor, and Capterra.
  • No specific employer reviews found for OphtAI directly.
  • General Reddit discussions about AI in ophthalmology suggest current AI tools may not be suitable for complex subspecialty discussions or nuanced imaging.

Based on reviews from: Google Search, Reddit, Evolucare, OphtAI website

Last updated: 2026-09-20

Videos

News, demos, and interviews about OphtAI.

Loading videos...

Videos load interactively. If none appear, search YouTube for OphtAI →

View all on YouTube

Press & Coverage

OphtAI
OphtAI at SANTEXPO 2026: AI for visual screening
OphtAI will be exhibiting at SANTEXPO 2026 to present its AI solution for retinal condition screening, emphasizing its ability to enhance clinicians' capabilities and provide detailed reports for various conditions. The company highlights its proven technology, developed using hundreds of thousands of images, for detecting diabetic retinopathy, glaucoma, and AMD.
2026-04
Evolucare
OphtAI : AI for ophthalmologists
This article discusses how AI is transforming ophthalmology by improving early detection of chronic conditions like diabetic retinopathy, glaucoma, and AMD, while optimizing medical resources. OphtAI is presented as a scientifically validated technology with performance comparable to human experts, offering consistent and detailed feedback.
2026-03
Evolucare
Evolucare OphtAI CE certified according to the MDR
OphtAI, a Class IIa medical device utilizing AI for automated retinal image analysis, has achieved MDR certification, a significant milestone for the company and the ophthalmic e-health sector. This certification, issued by GMED (0459), confirms the clinical reliability, technical robustness, and regulatory compliance of the technology.
2025-12
OphtAI
AI in teleophthalmology: towards optimised eye screening
This article highlights the integration of OphtAI's artificial intelligence into daily clinical workflow for fundus analysis, with orthoptists capturing images and AI providing rapid, comprehensive reports. This semi-automated approach optimizes case processing time and allows practitioners to focus on complex cases.
2025-10
PubMed (Klin Monbl Augenheilkd)
Automated Diabetic Retinopathy Screening in Out-patient Diabetes Care - Comparison of Two Artificial Intelligence Algorithms: RetCAD and OphtAI - PubMed
A study compared two AI algorithms, RetCAD and OphtAI, for automated diabetic retinopathy screening in outpatient diabetes care. OphtAI version 2.3.4 achieved a sensitivity of 70% and a specificity of 100% for detecting referable DR, with both algorithms correctly identifying severe and proliferative DR.
2025-05
Evolucare
OphtAI at the SFO 2025 Congress: spotlight on ophthalmological AI
OphtAI will be showcasing its AI solution for ophthalmological screening at the French Ophthalmology Society (SFO) Congress in May 2025, featuring new clinical indicators and a new user experience with MyOphtAI. The company emphasizes its strong ecosystem of integrators and partners, including Topcon and Optomed.
2025-04
Topcon Healthcare
Topcon Healthcare and OphtAI Announce their Partnership in EMEA
Topcon Healthcare Solutions and OphtAI have partnered to integrate OphtAI's AI technology into Topcon's Harmony Referral System, providing eye care professionals with enhanced access to AI services for early detection of eye pathologies. OphtAI's CE-marked AI can detect diabetic retinopathy, macular edema, glaucoma, and AMD.
2023-02
PR Newswire
Optomed signs an industrial partnership with a French AI company OphtAI
Optomed and OphtAI have formed a commercial collaboration to sell OphtAI's CE-marked AI for detecting diabetic retinopathy, glaucoma, and AMD, alongside Optomed Aurora handheld cameras. This partnership aims to make eye screening more accessible in Europe and Canada.
2022-03

Frequently Asked Questions

OphtAI specializes in AI solutions for analyzing retinal images. Their primary focus is on detecting and characterizing diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD) to aid in early screening and diagnosis.
OphtAI's technology is designed for seamless integration into current tele-ophthalmology platforms. It typically requires digital retinal images, which can be uploaded to their AI analysis system, providing rapid results to support remote diagnosis and patient management.
OphtAI's solutions are developed with a strong emphasis on regulatory compliance. They have obtained CE marking as a class IIa medical device in Europe, and are actively pursuing FDA clearance in the United States.
OphtAI's AI algorithms have undergone rigorous validation processes, demonstrating high accuracy in detecting and classifying diabetic retinopathy, glaucoma, and AMD. Their performance is often benchmarked against expert human graders to ensure reliability and clinical utility.
OphtAI typically offers flexible pricing models that can be adapted to the scale of implementation, from individual clinics to large healthcare networks. Their packages usually include technical support, software updates, and ongoing assistance to ensure optimal performance and user satisfaction.
OphtAI actively collaborates with various partners, including leading ophthalmology clinics, research institutions, and technology providers. These partnerships aim to further validate their AI solutions, expand their reach, and integrate their technology into broader healthcare ecosystems.
OphtAI is committed to long-term growth and innovation in the AI healthcare sector. They are backed by strategic investments and have a clear roadmap for expanding their product offerings and market presence, ensuring stability and continuous development in the dynamic field of ophthalmic AI.

Related Companies

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]

The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

Prenaital is an AI-driven healthcare company focused on revolutionizing maternal care by improving the early detection and management of high-risk pregnancies. Their AI models analyze ultrasound images to identify at-risk pregnancies, including those with abnormal fetal growth and a risk of preterm birth, with significantly higher accuracy than current clinical practices—detecting 25-50% more high-risk cases. […]

PHQ Screeners is a free, open-access resource maintained by Pfizer, providing a comprehensive suite of Patient Health Questionnaire (PHQ) and Generalized Anxiety Disorder (GAD-7) screening instruments. These tools were developed by Drs. Robert L. Spitzer, Janet B.W. Williams, and Kurt Kroenke with an educational grant from Pfizer, and are widely utilized in primary care and […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.